Dissatisfaction with body image is common among men receiving androgen deprivation therapy (ADT), a new study has shown. Exercise is seen as a means to counterbalance the side effect of treatment and improve mood.
Treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib has demonstrated clinical activity both in heavily pretreated advanced breast cancer patients carrying a germline BRCA 1/2 mutation, according to the results of the phase II ABRAZO study.
Stereotactic ablative radiotherapy has shown its capability as a treatment option in patients with renal cell carcinoma in a solitary kidney, achieving excellent oncologic outcomes as well as having an acceptable impact on renal function, according to an analysis of the IROCK (International Radiosurgery Oncology Consortium for Kidney) database.
Patients with a positive post-treatment biopsy after external beam radiotherapy are at higher risk of distant metastasis and prostate cancer-related death, suggests a recent study. Positive post-treatment biopsies are more frequent in the setting of external beam radiotherapy alone without androgen deprivation therapy or in the presence of high-risk disease.
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.